Basic Search
|
Summaries
|
Advanced Search
Violation Tracker UK Parent Company Summary
Parent Company Name: Nordic Capital
Ownership Structure: privately held
Headquartered in: Sweden
Major Industry: private equity (including portfolio companies)
Specific Industry: private equity (including portfolio companies)
Penalty total since 2010: £94,502,933
Number of cases: 6
| Top Offence Groups (Groups Defined) | Penalty Total | Number of Cases |
| competition-related offences | £94,502,933 | 6 |
| Top Offence Types | Penalty Total | Number of Cases |
| price-fixing or anti-competitive practices | £94,502,933 | 6 |
Note: Parent-subsidiary linkages are based on current relationships and may vary from what was the case when a violation occurred.
Individual Penalty Cases:
Click on the company or penalty amount for more information on each case.
Download results as
CSV
or
XML
(maximum 1000; for access to larger downloads contact
Phil Mattera)
| Company | Offence Type | Year | Agency  . | Penalty Amount |
| Advanz Pharma | price-fixing or anti-competitive practices | 2021 | UK-CMA | £40,900,000 |
| Advanz Pharma | price-fixing or anti-competitive practices | 2021 | UK-CMA | £43,000,000 |
| Focus Pharmaceuticals Limited and Focus Pharma Holdings Limited | price-fixing or anti-competitive practices | 2022 | UK-CMA | £549,343 |
| Focus Pharmaceuticals Ltd. and Focus Pharma Holdings Ltd. and Mercury Pharma Group Ltd. | price-fixing or anti-competitive practices | 2022 | UK-CMA | £921,357 |
| Focus Pharmaceuticals Limited and Mercury Pharma Group Ltd. and Cinven Partners LLP et al. | price-fixing or anti-competitive practices | 2022 | UK-CMA | £1,843,380 |
| Focus Pharmaceuticals Limited and Mercury Pharma Group Ltd. and Concordia Investments (Jersey) Ltd. and Advanz Pharma Corp. Ltd. et al. | price-fixing or anti-competitive practices | 2022 | UK-CMA | £7,288,853 |
